For a small biotech sponsor running a mid-stage dermatology or oncology trial, the contract research organization invoice is often the single largest line item between the lab and the FDA. Vial, a San Francisco company founded in 2020 by Andrew Brackin and Simon Burns, is pitching those sponsors on a simple proposition: the same protocol, run faster and at lower cost, by a CRO built on modern software rather than two decades of stitched-together vendor systems [Vial].
The patients on the other end of that pitch are the ones who matter most. Vial's disclosed therapeutic focus spans oncology, gastroenterology, and dermatology, areas where standard of care varies widely. A patient with moderate-to-severe atopic dermatitis today typically cycles through topical corticosteroids and calcineurin inhibitors before stepping up to biologics like dupilumab or newer JAK inhibitors, with response rates that still leave a meaningful share of patients undertreated. In oncology, standard of care is increasingly defined by biomarker-matched regimens layered on top of chemotherapy or immunotherapy backbones, and trial enrollment remains the rate limiter for getting the next option to patients. Anything that compresses the timeline from protocol to readout is, in principle, a patient-outcomes story before it is a margin story.
The bet
Vial operates as a tech-enabled CRO, selling trial execution services to biotech sponsors and layering its own software across site coordination, data capture, and monitoring [General Catalyst]. The company also describes work on computationally designed therapeutics and automated trials [Vial website]. The wedge, based on the public materials, is the CRO services business: sponsors pay Vial to run their studies, and Vial argues it can do so at lower cost than incumbent CROs because its internal tooling reduces the manual labor that drives traditional bids. In November 2023, Vial added NEXT Oncology to its trial site network, a move that gave it access to early-phase oncology patients through an established Phase 1 specialist [FierceBiotech].
Why it could be big
The CRO market is large, concentrated, and structurally slow. A handful of incumbents handle most pharma trials, and biotech sponsors, particularly those running their first or second program, often complain about pricing opacity and timeline slippage. General Catalyst led Vial's $67 million round, with Byers Capital and BoxGroup also on the cap table [Crunchbase News]. General Catalyst's public note on the investment frames Vial as a rebuild of the CRO operating model rather than a feature on top of it [General Catalyst]. If even a modest share of small and mid-cap biotech sponsors route their next trial through a software-first CRO, the revenue math becomes interesting quickly: Phase 2 oncology trials routinely run into the tens of millions of dollars per study.
The regulatory backdrop is also more permissive than it was five years ago. The FDA's guidance on decentralized clinical trials, finalized in recent cycles, and parallel signals from the EMA on remote data capture and risk-based monitoring, give tech-forward CROs more room to design studies that do not depend on the traditional all-in-person site model. Vial's competitors Medable and Science 37 have built businesses on adjacent versions of this thesis [CBInsights].
Team and traction
Brackin and Burns were early team members at Robinhood, Opendoor, and Newfront before starting Vial [Vial job description via drawerrr.com]. The early team draws from Apple, Google, Faire, Chime, and TPG Capital [Vial job description via drawerrr.com]. Headcount was reported at roughly 179 employees as of November 2024 [LeadIQ], a meaningful operating footprint for a company at the Series A stage. Open roles on Vial's Lever page include a Clinical Trial Lead, a Scientific Writer, and a Chief of Staff [Lever.co], a mix that suggests continued investment in both clinical operations and the central team.
Series A funding ($M) | 67 | $M
Reported headcount Nov 2024 | 179 | employees
(Note: the two figures above are on different units and are shown for reference rather than direct comparison.)
| Item | Detail | Source |
|---|---|---|
| Series A | $67M, led by General Catalyst | [Crunchbase News] |
| Co-investors | Byers Capital, BoxGroup | [Crunchbase News] |
| Site network addition | NEXT Oncology, Nov 2023 | [FierceBiotech] |
| Therapeutic areas cited | Oncology, GI, dermatology | [Vial] |
The honest counterfactual
What bears will say is that the tech-enabled CRO category has a mixed track record. Science 37, an early pioneer of decentralized trials, went public via SPAC and later faced significant valuation compression, a reminder that biotech sponsors are conservative buyers and that switching CROs mid-program is rare [CBInsights]. The bull answer, supported by Vial's NEXT Oncology tie-up and General Catalyst's continued backing, is that the company is building a hybrid model: real trial sites with real investigators, wrapped in software, rather than a purely virtual offering that asks sponsors to abandon the site-based model regulators are most comfortable with [FierceBiotech] [General Catalyst]. That is a more incremental, and arguably more durable, wedge than the first wave of decentralized-trial pure plays attempted.
There is also the peer-review question that hangs over any company describing work on computationally designed therapeutics. Vial has not, in the public record reviewed here, disclosed clinical-stage assets of its own with published readouts. Until any internally originated program reaches a peer-reviewed milestone or a registered trial with reported outcomes, the therapeutics narrative should be read as forward-looking, and the CRO services business as the one carrying the company today.
What to watch
The next twelve months will turn on three things. First, sponsor logos: Vial has not publicly named the biotech customers running trials through its network, and a handful of disclosed Phase 2 sponsors would meaningfully de-risk the commercial story. Second, regulatory milestones from any trial Vial is operating, particularly in oncology through the NEXT Oncology relationship, where readouts move share prices and reputations. Third, the shape of the next financing. A Series B in the current biotech funding climate would test whether software-CRO multiples have recovered from the 2022 to 2023 reset.
For patients waiting on the next dermatology biologic or the next targeted oncology combination, the question is narrower and more concrete: does a trial run by Vial enroll faster, read out sooner, and get a working therapy to a label more quickly than the alternative. That is the outcome to track, and it is the one the company will eventually be judged on.
Pulse Raman, Health and Bio Correspondent, Startuply.